Viatris Inc. Stock

Equities

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq 04:00:02 2024-05-31 pm EDT 5-day change 1st Jan Change
10.6 USD +1.10% Intraday chart for Viatris Inc. +1.78% -2.17%
Sales 2024 * 14.99B Sales 2025 * 14.81B Capitalization 12.62B
Net income 2024 * 1.81B Net income 2025 * 900M EV / Sales 2024 * 1.74 x
Net Debt 2024 * 13.43B Net Debt 2025 * 11.64B EV / Sales 2025 * 1.64 x
P/E ratio 2024 *
7.98 x
P/E ratio 2025 *
13.2 x
Employees 33,000
Yield 2024 *
4.74%
Yield 2025 *
4.87%
Free-Float 96.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.10%
1 week+1.78%
Current month-0.05%
1 month-8.43%
3 months-14.35%
6 months+15.41%
Current year-2.17%
More quotes
1 week
10.24
Extreme 10.24
10.64
1 month
10.24
Extreme 10.24
12.04
Current year
10.24
Extreme 10.24
13.62
1 year
8.74
Extreme 8.74
13.62
3 years
8.42
Extreme 8.42
15.92
5 years
8.42
Extreme 8.42
23.11
10 years
8.42
Extreme 8.42
76.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 22-12-28
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - 20-11-15
Members of the board TitleAgeSince
Chairman 56 20-11-15
Director/Board Member 68 20-11-15
Director/Board Member 66 20-11-15
More insiders
Date Price Change Volume
24-05-31 10.6 +1.15% 8,862,334
24-05-30 10.48 +1.65% 5,823,176
24-05-29 10.31 -0.77% 5,739,908
24-05-28 10.39 -0.19% 6,165,865
24-05-24 10.41 -1.14% 4,900,638

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Company’s ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
10.6 USD
Average target price
12.33 USD
Spread / Average Target
+16.34%
Consensus